Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-04-04 12:52 pm Purchase | 2024-03-15 | 13G | Ventyx Biosciences, Inc. VTYX | James E. Flynn | 3,542,000 5.030% | 3,542,000 (New Position) | Filing History |
| 2024-03-22 5:44 pm Purchase | 2024-03-15 | 13D | BiomX Inc. PHGE | James E. Flynn | 611,010 11.060% | 611,010 (New Position) | Filing History |
| 2024-03-15 4:37 pm Purchase | 2024-03-14 | 13D | Larimar Therapeutics, Inc. LRMR | James E. Flynn | 21,273,474 33.320% | 8,300 (+0.04%) | Filing History |
| 2024-02-16 2:11 pm Purchase | 2024-02-16 | 13D | Larimar Therapeutics, Inc. LRMR | James E. Flynn | 21,265,174 34.820% | 4,291,539 (+25.28%) | Filing History |
| 2024-02-15 5:20 pm Unchanged | 2024-02-13 | 13D | Larimar Therapeutics, Inc. LRMR | James E. Flynn | 16,973,635 39.200% | 0 (Unchanged) | Filing History |
| 2024-02-12 5:34 pm Purchase | 2023-12-31 | 13G | Nuvalent, Inc. NUVL | James E. Flynn | 25,477,776 35.010% | 6,110 (+0.02%) | Filing History |
| 2024-02-12 5:33 pm Sale | 2023-12-31 | 13G | Nuo Therapeutics, Inc. AURX | James E. Flynn | 2,183,164 5.160% | -516,836 (-19.14%) | Filing History |
| 2024-02-12 5:33 pm Purchase | 2023-12-31 | 13G | Kura Oncology, Inc. KURA | James E. Flynn | 5,312,733 7.150% | 938,689 (+21.46%) | Filing History |
| 2024-02-12 5:32 pm Purchase | 2023-12-31 | 13G | Merus N.V. MRUS | James E. Flynn | 3,019,901 5.230% | 639,463 (+26.86%) | Filing History |
| 2024-02-12 5:32 pm Purchase | 2023-12-31 | 13G | Deciphera Pharmaceuticals, Inc. DCPH | James E. Flynn | 5,788,024 7.190% | 1,160,714 (+25.08%) | Filing History |
| 2024-02-12 5:31 pm Purchase | 2023-12-31 | 13G | Catalyst Pharmaceuticals, Inc. CPRX | James E. Flynn | 8,888,901 8.340% | 3,004,453 (+51.06%) | Filing History |
| 2024-02-12 5:31 pm Sale | 2023-12-31 | 13G | Vigil Neuroscience, Inc. VIGL | James E. Flynn | 1,173,523 3.270% | -878,487 (-42.81%) | Filing History |
| 2024-02-12 5:31 pm Sale | 2023-12-31 | 13G | Singular Genomics Systems, Inc. OMIC | James E. Flynn | 250,496 6.830% | -13,393 (-5.08%) | Filing History |
| 2024-02-12 5:30 pm Sale | 2023-12-31 | 13G | Pulmonx Corporation LUNG | James E. Flynn | 6,009 0.020% | -2,459,254 (-99.76%) | Filing History |
| 2024-02-12 5:30 pm Purchase | 2023-12-31 | 13G | Prelude Therapeutics Incorporated PRLD | James E. Flynn | 4,133,000 9.850% | 910,310 (+28.25%) | Filing History |
| 2024-02-12 5:29 pm Purchase | 2023-12-31 | 13G | Owens & Minor, Inc. OMI | James E. Flynn | 5,229,779 6.840% | 1,027,112 (+24.44%) | Filing History |
| 2024-02-12 5:28 pm Purchase | 2023-12-31 | 13G | Oscar Health, Inc. OSCR | James E. Flynn | 11,246,820 5.890% | 709,329 (+6.73%) | Filing History |
| 2024-02-12 5:27 pm Sale | 2023-12-31 | 13G | MALLINCKRODT PLC SHS MNKTQ | James E. Flynn | 1,281,233 6.500% | -224,736 (-14.92%) | Filing History |
| 2024-02-12 5:27 pm Purchase | 2023-12-31 | 13G | HilleVax, Inc. HLVX | James E. Flynn | 4,004,231 8.270% | 1,310,130 (+48.63%) | Filing History |
| 2024-02-12 5:26 pm Purchase | 2023-12-31 | 13G | Enhabit, Inc. EHAB | James E. Flynn | 4,997,746 9.970% | 2,001,746 (+66.81%) | Filing History |